Sphingosine kinase 2 supports the development of BCR/ABL-independent acute lymphoblastic leukemia in mice.
Vicki XieDaochen TongCraig T Wallington-BeddoeKen F BradstockLinda J BendallPublished in: Biomarker research (2018)
These results show that the role of SphK2 in ALL development is not limited to BCR/ABL1 driven disease extending the potential use of inhibitors of this enzyme to ALL patients whose disease have driver mutations other than BCR/ABL1.
Keyphrases
- tyrosine kinase
- acute lymphoblastic leukemia
- chronic myeloid leukemia
- end stage renal disease
- ejection fraction
- allogeneic hematopoietic stem cell transplantation
- chronic kidney disease
- newly diagnosed
- prognostic factors
- peritoneal dialysis
- metabolic syndrome
- skeletal muscle
- risk assessment
- climate change
- high fat diet induced
- patient reported